Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FRTXNASDAQ:GDTCNASDAQ:MIRANYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGDTCCytoMed Therapeutics$2.05+1.5%$2.32$1.20▼$4.05$22.43M-0.3378,440 shs1,218 shsMIRAMIRA Pharmaceuticals$1.40+2.2%$1.12$0.51▼$5.01$23.69M1.932.20 million shs140,274 shsVORVor Biopharma$0.22+0.1%$0.44$0.13▼$1.80$27.97M-0.511.03 million shs607,042 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+6.12%GDTCCytoMed Therapeutics-0.05%-11.64%-10.79%-24.35%-4.21%MIRAMIRA Pharmaceuticals+2.19%+3.70%+19.76%+38.61%+79.46%VORVor Biopharma+0.09%+11.96%-58.21%-77.62%-82.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGDTCCytoMed Therapeutics1.5122 of 5 stars3.53.00.00.00.00.00.0MIRAMIRA Pharmaceuticals3.1997 of 5 stars3.75.00.00.03.80.00.6VORVor Biopharma3.3251 of 5 stars4.25.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGDTCCytoMed Therapeutics 3.00Buy$5.00143.90% UpsideMIRAMIRA Pharmaceuticals 3.33Buy$14.00900.00% UpsideVORVor Biopharma 2.40Hold$7.063,053.33% UpsideCurrent Analyst Ratings BreakdownLatest FRTX, VOR, MIRA, and GDTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $0.403/21/2025VORVor BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/21/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.50 ➝ $13.003/21/2025VORVor BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GDTCCytoMed Therapeutics$69.50K322.69N/AN/A$0.78 per share2.63MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGDTCCytoMed Therapeutics-$3.13MN/A0.00∞N/AN/AN/AN/A7/28/2025 (Estimated)MIRAMIRA Pharmaceuticals-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)VORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest FRTX, VOR, MIRA, and GDTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRTXFresh Tracks TherapeuticsN/AN/AN/AGDTCCytoMed Therapeutics0.0421.54N/AMIRAMIRA PharmaceuticalsN/A6.116.11VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRTXFresh Tracks Therapeutics25.04%GDTCCytoMed Therapeutics0.04%MIRAMIRA Pharmaceuticals35.16%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipFRTXFresh Tracks Therapeutics0.23%GDTCCytoMed TherapeuticsN/AMIRAMIRA Pharmaceuticals6.65%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGDTCCytoMed TherapeuticsN/A10.94 millionN/ANot OptionableMIRAMIRA Pharmaceuticals216.92 million15.46 millionNot OptionableVORVor Biopharma140124.96 million65.45 millionNot OptionableFRTX, VOR, MIRA, and GDTC HeadlinesRecent News About These CompaniesVor Bio details extent of Cambridge layoffs in state filingJune 2, 2025 | bizjournals.comCambridge biotech company researching blood cancers to close, lay off 155June 2, 2025 | masslive.comVor Biopharma Inc. Advanced Charts - Barron'sMay 29, 2025 | barrons.comRA Capital's biotech incubator lays off staffers: StatMay 15, 2025 | fiercebiotech.comStifel cuts Vor Biopharma stock rating amid clinical and financial concernsMay 10, 2025 | investing.comJMP Securities Downgrades Vor Biopharma (VOR)May 10, 2025 | msn.comVor Biopharma draws downgrades on strategic reviewMay 9, 2025 | msn.comJones Trading cuts Vor Biopharma stock rating to HoldMay 9, 2025 | investing.comHC Wainwright & Co. Downgrades Vor Biopharma (VOR)May 9, 2025 | msn.com4 more biotechs cut staff amid market tumultMay 9, 2025 | biopharmadive.comBlood cancer biotech Vor Bio ends clinical work, lays off 95% of staffMay 8, 2025 | endpts.comVor Bio Winding Down Operations, Cutting Workforce, Exploring Potential SaleMay 8, 2025 | marketwatch.comVor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | finanznachrichten.deVor Biopharma stock plummets on operation wind-downMay 8, 2025 | in.investing.comVor Bio to wind down, halting cell therapy trials and shedding most staffMay 8, 2025 | fiercebiotech.comVor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | globenewswire.comVor Biopharma faces Nasdaq delisting over low stock priceApril 27, 2025 | investing.comVor Bio price target lowered to $5 from $12 at StifelMarch 22, 2025 | markets.businessinsider.comVor Bio price target lowered to $13 from $17.50 at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateMarch 21, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBig Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025By Nathan Reiff | May 15, 2025View Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025Retail Investors Are Betting Big on Rocket Lab—Should You Too?By Ryan Hasson | May 16, 2025View Retail Investors Are Betting Big on Rocket Lab—Should You Too?Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?By Thomas Hughes | May 22, 2025View Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?By Nathan Reiff | May 10, 2025View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?FRTX, VOR, MIRA, and GDTC Company DescriptionsFresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.CytoMed Therapeutics NASDAQ:GDTC$2.05 +0.03 (+1.49%) Closing price 06/6/2025 03:49 PM EasternExtended Trading$2.10 +0.05 (+2.20%) As of 06/6/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.MIRA Pharmaceuticals NASDAQ:MIRA$1.40 +0.03 (+2.19%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.38 -0.01 (-1.07%) As of 06/6/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Vor Biopharma NYSE:VOR$0.22 +0.00 (+0.09%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.22 0.00 (-1.25%) As of 06/6/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
